NVEC

ANALYST NOTE: NVE CORPORATION (NVEC) Date: June 13, 2026

1. Structural Readiness

Conservative Entry: $82.36 Current Price: $110.46 Extension: +34.1% vs. conservative entry

2. Thesis Layer

Primary Secular Thesis: Reshoring & Industrial Automation (Robotics & Automation) Thesis Weighting: Moderate to High

NVE Corporation is positioned as a direct beneficiary of the Reshoring & Industrial Automation theme. The company's core competency in spintronics and high-performance sensors addresses the specific infrastructure needs of modern factory automation, where higher-speed data transmission and channel density are critical as manufacturing expands. Management explicitly identified the "Industrial Internet of Things (IIoT)" and "Artificial Intelligence of Things (AIoT)" as major markets for standard sensors, citing the need for components that can detect magnetic or metallic materials with precision in automated environments.

Secondary Secular Thesis: Defense Modernization (C4ISR / Sensors / EW) Thesis Weighting: Low to Moderate

The company also holds exposure to Defense Modernization. Management has stated expectations for defense sales to increase significantly in the fiscal year ending March 31, 2027. While the confidence in this specific tier is noted as lower in the context of the broader market, the direct link to C4ISR and sensor technology provides a secondary structural tailwind. The combination of these two themes—industrial automation and defense—provides a diversified secular backdrop, though the industrial automation thesis currently carries the heavier weight regarding immediate revenue drivers and product fit.

3. Business Overview

Business Model & Industry: NVE Corporation operates in the Technology sector, specializing in the development and sale of advanced devices that leverage spintronics, a nanotechnology utilizing electron spin for data acquisition, storage, and transmission. The company manufactures high-performance spintronic products, including sensors and couplers, and engages in contract-based research and development (R&D) and licensing of its magnetoresistive random access memory (MRAM) technology.

Operational Evidence (as of June 13, 2026):

• Revenue Growth: The company reported a 5% year-over-year increase in fourth-quarter total revenue to $7.65 million (Fiscal Q4 2026). Furthermore, the third quarter of fiscal 2026 saw a 23% increase in revenue compared to the same period in the prior year.
• Market Drivers: The increase in product sales was attributed to growth in both defense and non-defense sectors, as well as expansion in both direct and distributor channels.
• Product Strategy: Management highlighted a "continuous flow of new products," including a recently announced wafer-level chip-scale sensor for medical and industrial applications. New equipment installed in the past quarter has already helped fill orders for high-performance TMR sensors.
• Customer Base: The company maintains a Supplier Partnering Agreement with Abbott Laboratories, which is valid through December 31, 2027. Medical devices are identified as an important market, leveraging product advantages in small size, low power, and reliability.
• Distribution: Products are distributed globally through more than 75 countries via partners including America II Electronics, Angst+Pfister Sensors and Power, and Digi-Key Corporation.
• Capital Allocation: The Board declared a cash dividend of $1.00 per share in January 2026. Management expects fixed asset purchases to decrease significantly in fiscal 2027 following the completion of current expansion projects.

4. Archetype and Conviction

Archetype: Quality Compounder

NVE fits the Quality Compounder archetype. The company demonstrates consistent revenue growth (23% QoQ in Q3 FY26, 5% in Q4 FY26), a strong balance sheet implied by the ability to pay dividends and fund R&D, and a clear strategic focus on high-margin, specialized technology (spintronics). The business model is supported by recurring contract R&D and a diversified customer base across medical, industrial, and defense sectors.

Conviction Stack:

• Thesis Strength: High. The alignment with Reshoring and Industrial Automation is direct, with management explicitly linking product demand to factory automation trends.
• Evidence Quality: Strong. The evidence base includes specific financial figures (revenue growth rates, dividend amounts), explicit management guidance on future sales trends, and confirmed customer agreements.
• Structural Quality: The setup shows a "productive" ATR at breakout (3.0%) and a "very high" current ATR (7.3%), indicating the stock has moved with conviction and is currently in a high-volatility regime typical of confirmed breakouts.
• Rerating Potential: Moderate to High. The completion of expansion projects (leading to reduced capex) combined with expected increases in defense and R&D contracts suggests an inflection point where operating leverage could improve margins.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• A significant deviation from management's guidance regarding the "significant increase" in defense sales or the "continued bright outlook" for product sales would weaken the fundamental thesis.

Strengthening Factors:

• Confirmation of the "significant" increase in defense sales in the upcoming fiscal year (ending March 2027).
• Continued acceleration in contract R&D revenue.
• Successful integration of new wafer-level sensors into high-volume production lines.

Evidence Gaps:

• Missing Evidence: There is no specific evidence provided in the current dataset regarding the exact gross margin percentages for the new wafer-level sensors or the specific dollar value of the "accelerated deductions" for R&D beyond the tax impact estimate.
• Missing Evidence: No data is available on the specific backlog size or order book value as of June 13, 2026, which would further quantify the "bright outlook."

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key risks: High current ATR (7.3%) indicating elevated volatility and potential for sharp pullbacks; Dependence on a limited number of key customers (e.g., Abbott); Potential for defense spending delays; Execution risk on new product ramp-up. Sizing hint: Position size should account for the very high current volatility; consider scaling in on pullbacks toward the breakout zone rather than chasing the 34% extension. Expected path: Management expects fixed asset purchases to decrease in FY27 as expansion completes, potentially improving free cash flow while revenue continues to grow from defense and industrial sectors. Expected horizon: 12 to 18 months for the thesis to fully play out through the completion of the fiscal year and realization of defense sales growth. Failure mode to watch: A sustained close below $65.01, which would indicate the structural support has failed and the thesis is no longer supported by price action.